Insider Trading March 16, 2026

Huntington CEO Purchases $499,970 in Stock as Analysts Reassess Forecasts

Stephen Steinour buys 32,277 shares while Wall Street updates price targets and EPS estimates amid integration concerns

By Nina Shah HBAN
Huntington CEO Purchases $499,970 in Stock as Analysts Reassess Forecasts
HBAN

Huntington Bancshares' chief executive, Stephen Steinour, purchased 32,277 shares on March 12, 2026, at $15.49 each, a block valued at $499,970. The transaction coincides with a wave of analyst notes that adjust price targets, earnings projections and assessments of integration risk following recent acquisitions.

Key Points

  • Huntington CEO Stephen Steinour bought 32,277 shares on March 12, 2026, at $15.49 per share, totaling $499,970.
  • Multiple brokerages updated their views: DA Davidson lowered its target to $20 but kept a Buy rating; Truist cut 2026 and 2027 EPS estimates while keeping a Buy and $21 target; Morgan Stanley remains Overweight and as a Top Pick with a $21 target but lowered 2027 EPS guidance to $1.90-1.93; Evercore ISI initiated coverage with an Outperform rating and $21 target.
  • These developments affect the banking and broader financials sector by altering near-term earnings expectations and highlighting integration risk following acquisitions.

Stephen Steinour, who serves as President, CEO and Chairman of Huntington Bancshares Inc (NASDAQ: HBAN), executed an open-market purchase of 32,277 shares of the company's common stock on March 12, 2026. The shares were acquired at $15.49 apiece, producing a total outlay of $499,970.

The insider purchase comes amid a flurry of analyst commentary and updated financial projections for Huntington. Several brokerage firms have restated their views on the bank, providing a mix of buy-side support and revised earnings guidance.


Recent analyst actions

  • DA Davidson lowered its price target for Huntington to $20 from $21 but kept a Buy rating, pointing to integration risks tied to recent acquisitions.
  • Truist Securities reaffirmed a Buy rating and a $21 price target, while trimming its earnings-per-share forecasts - cutting 2026 EPS from $1.70 to $1.60 and reducing the 2027 estimate from $2.00 to $1.92.
  • Morgan Stanley continues to carry an Overweight rating with a $21 price objective, although it updated its 2027 EPS expectation to a range of $1.90-1.93 and noted the bank has underperformed recently. Morgan Stanley also retains Huntington as its Top Pick.
  • Evercore ISI initiated coverage with an Outperform rating and a $21 target, highlighting the enlarged footprint in higher-growth geographies such as Texas and the Southeast following the Cadence acquisition.

These analyst moves underscore divergent assessments of Huntington's near-term profit trajectory and the execution risk associated with integrating recent deals. The mix of maintained Buy/Outperform stances and lowered earnings estimates reflects continued interest in the franchise alongside caution about near-term earnings momentum.


Contextual note - The transaction by the chief executive signals a personal capital commitment at the stated price, while the analyst commentary provides contemporaneous market views that adjust expectations for near-term earnings and reflect strategic considerations tied to recent acquisitions.

Risks

  • Integration risk from recent acquisitions - explicitly cited by DA Davidson as a reason for a reduced price target, which could affect execution and near-term performance in banking and financials.
  • Revised earnings uncertainty - Truist and Morgan Stanley lowered EPS forecasts for 2026 and 2027, indicating potential pressure on reported earnings that impacts investor valuation of bank stocks.
  • Recent underperformance - Morgan Stanley noted underperformance, introducing uncertainty about the stock's near-term market reception despite maintained ratings.

More from Insider Trading

Marvell Technology President Sells $1.1M in Stock as Shares Trade Near Yearly High Apr 6, 2026 Edward Lampert Sells $58.5 Million in Lands’ End Stock; Company Posts Q4 Shortfall, Announces $100M Buyback Program Apr 6, 2026 NeonC/NeOnc President Buys $153,398 in Stock as Company Advances Financing and Clinical Timeline Apr 6, 2026 Edwards Lifesciences Executive Executes Option Exercise, Sells 1,019 Shares Apr 6, 2026 Penumbra Director Executes $32,822 Stock Sale Amid Deal and Upbeat Quarterly Results Apr 6, 2026